Content generated by AI editorial engine. Editorially supervised by Sedat ANAK.
The median of 12 price targets is $340[FMP target], stock is $274, +24.1% vs the analyst consensus median. Q2 FY26 EPS $7.78 vs $7.60 estimate: beat (+2.4%)[FMP earnings]. Stock move on D+1: -3.0%.
A- — FMP rating [FMP ratings]. Form 4: unavailable[FMP Form 4].
Quick AnswerCigna Corporation (CI) Q3 consensus: revenue $72.7B[FMP est], EPS $7.50[FMP est]. 6 consecutive quarters of beat[FMP earnings].
Q2 FY26 EPS $7.78 vs $7.60 estimate: beat (+2.4%)[FMP]. Stock move on D+1: -3.0%[FMP D+1].
Watchlist
Evernorth Specialty Growth
evernorth_specialty_growth
Evernorth's Specialty and Care Services business delivered strong adjusted earnings growth of 20% in Q1 2026, driven by attractive volume growth and demand for specialty drugs.
"Specialty and Care Services showed strong growth with pretax adjusted earnings up 20% to $1.1 billion. This performance reflects continued momentum in our fastest-growing business, including strong demand for specialty drugs and increased biosimilar and specialty generic adoption, which are key levers for delivering affordability and value to patients and clients."
- Ann Dennison, CFO - Q1 FY26 Earnings Call - April 30, 2026
Fy26 Eps Guidance Raise
fy26_eps_guidance_raise
Cigna Group has raised its full year 2026 adjusted EPS outlook to at least $30.35, reflecting strong first-quarter performance and disciplined execution.
"With our performance, we are raising our full year 2026 adjusted EPS outlook to at least $30.35, reflecting our disciplined approach and steady execution in an operating environment that continues to be shaped by many forces."
- David Cordani, CEO - Q1 FY26 Earnings Call - April 30, 2026
Ai Driven Personalization Affordability
ai_driven_personalization_affordability
Cigna is leveraging AI and advanced analytics to enhance customer experience, drive affordability, and personalize health services, leading to a 20% drop in inbound calls for digitally eligible customers.
"The combination of our AI tools and contact centers and improved customer digital experiences led to a 20% drop in total inbound calls for digitally eligible customer in our Cigna Healthcare U.S. employer business and a 25% reduction for pharmacy benefit services members when compared to just 2 years ago."
- Brian Evanko, President and COO - Q1 FY26 Earnings Call - April 30, 2026
Individual Exchange Exit
individual_exchange_exit
Cigna plans to exit its individual exchange business at the end of 2026 to sharpen focus on core platforms where it can deliver differentiated value.
"First, we are planning to exit our individual exchange business at the end of this year. We did not make this decision lightly and appreciate the importance of ensuring patients have continuity through the transition."
- Brian Evanko, President and COO - Q1 FY26 Earnings Call - April 30, 2026
Stock Expert AI - Methodology
Historical V1 earnings-model score (archived, Aug 12, 2026) — not the current MoonshotScore. Current MoonshotScore: CI stock page
multi-pillar methodology. News Sentiment strong. Revenue Growth weak.
How is it calculated? ->6 investor frameworks. 2 bullish (Ray Dalio, Buffett), 1 bearish (Ken Griffin), 3 neutral (Jim Simons, Klarman, Munger).
How is it calculated? ->Quality business, trading at fair value.
How is it calculated? ->Past Performance
Q2 FY26 (April 30, 2026) EPS $7.78 vs $7.60 estimate: beat (+2.4%)[FMP]. Stock move on D+1: -3.0%[FMP D+1].
Q2 FY26 EPS $7.78 vs $7.60 estimate: beat (+2.4%)[FMP]. Stock move on D+1: -3.0%[FMP].
No RPO/backlog concentration disclosed in Q1 earnings call.
Q1 CapEx $297.0M[FMP cashflow]. Q1 op margin 3.7%[FMP op margin] - this level in Q1 is sensitive to CapEx revision risk.
Not advice - a structural framework for earnings night. Decision discipline is yours.
Market Outlook
You read it in 5 minutes. When the numbers come out on Thursday evening - you know what you're looking at.
Data arrives at night. The framework is ready now.
Data arrives on Thursday evening. The framework is ready on this page: Q3 EPS threshold $7.50[FMP], CapEx threshold "below $297.0M". Two anchors, three scenarios.
Comparison Stock Expert AI is free today — no credit card.
Seeking Alpha $299/yr - analyst opinions + earnings coverage TipRanks $360/yr - Smart Score (1-10) + analyst consensus + insider trades Trendspider $400/yr - AI pattern detection + automated TA + multi-timeframe alerts
Prices as of April 2026. Sources: seekingalpha.com/subscriptions - tipranks.com/pricing - trendspider.com/pricing
Stock Expert AI is free today — no credit card. Council 7-lens analysis + MoonshotScore multi-pillar + Insider tracker + Technical levels - all in one platform, for every stock.
Educational tool, not investment advice. Past performance does not guarantee future results.
Calendar
DATA GAP: Events not in the FMP /stable/calendar feed - Investor day, analyst day, product launches, regulatory dates. These require company IR page scraping or manual calendar entry.
This Cigna Corporation (CI) Q3 FY26 earnings preview covers the analyst consensus, key catalysts, and what to watch on the earnings call.
Cigna Corporation (CI): Consensus EPS, revenue guidance, segment growth rates, and the tone of management commentary — the full breakdown with sources is on this page.
Cigna Corporation (CI): Figures are sourced from Financial Modeling Prep (FMP) fundamentals and consensus data plus official earnings-call transcripts; derived metrics are labeled with their source next to each figure.
Cigna Corporation (CI): No. This page is educational research, not investment advice. It summarizes analyst consensus and company data; consult a licensed financial advisor before making any investment decision.